Orlando Florete, MD
Pain Medicine · Jacksonville, FLNPI 1104922541
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $64,378 of the $86,099 with a category attached, or 74.8%. 49 manufacturers reported payments, led by Salix Pharmaceuticals, A Division Of Bausch Health US, LLC at 37.3% of the total. Reporting peaked in 2019 at $50,066 and has fallen 97.0% since, to $1,479 in 2025. Among pain medicine clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 455 payments — averaging $189.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$32K
- Idorsia Pharmaceuticals US Inc$24K
- Daiichi Sankyo Inc.$22K
- Collegium Pharmaceutical, Inc.$1K
- AbbVie$861
- Amgen$782
- plus $5K from 43 others
What the payments were for
- Consulting fees$3,0003%
- Speaking & faculty fees$64,37875%
- Travel & lodging$7,8259%
- Food & beverage$10,87513%
- Education$210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LUCEMYRA$24,375
- QUVIVIQ$23,646
- Morphabond ER$21,753
- RELISTOR$20,852
- AIMOVIG$479
- INTELLIS ADAPTIVESTIM$284
- NURTEC ODT$239
- SPRINT PNS System$153
- Proclaim Family of SCS IPGs$150
- NEUROSTAR TMS THERAPY SYSTEM$136
- VANTA ADAPTIVESTIM$134
- VYEPTI$125
- QULIPTA$116
- UBRELVY$116
- INCEPTIV$108
- XTAMPZA$105
How this compares
$86,099 in reported general payments places this provider in the 95th percentile of 596 pain medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xtampza ErOxycodone Myristate | 161 | $82,372 |
| RelistorMethylnaltrexone Bromide | 34 | $81,322 |
| OxycontinOxycodone Hcl | 117 | $70,236 |
| Buprenorphine | 178 | $37,734 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 796 | $31,235 |
| BelsomraSuvorexant | 54 | $24,702 |
| UbrelvyUbrogepant | 16 | $21,757 |
| Morphine Sulfate ErMorphine Sulfate | 502 | $17,124 |
| MounjaroTirzepatide | 12 | $12,544 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 396 | $12,075 |
| Oxycodone Hcl | 608 | $10,977 |
| MovantikNaloxegol Oxalate | 23 | $10,593 |
| QuviviqDaridorexant Hcl | 18 | $8,613 |
| Gabapentin | 485 | $6,164 |
| Oxymorphone Hcl ErOxymorphone Hcl | 15 | $6,142 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er | $1,409 | $82,372161 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $32,142 | $81,32234 claims |
| Hikma Pharmaceuticals USABuprenorphine, Buprenorphine-Naloxone, Morphine Sulfate | $43 | $47,917337 claims |
| MerckBelsomra | $109 | $24,70254 claims |
| AbbVieUbrelvy | $861 | $21,75716 claims |
| Lilly USA, LLCMounjaro | $119 | $12,54412 claims |
| Redhill Biopharma Inc.Movantik | $108 | $10,59323 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $23,969 | $8,61318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 596 pain medicine providers in Florida.
Other pain medicine in Jacksonville
- Mark-Friedrich HurdleJacksonville$140K
- Christopher NetzelJacksonville$34K
- Andrew MedvedovskyJacksonville$32K
- Sahil GuptaJacksonville$19K
- Pavel BalduyeuJacksonville$18K
- Jeffrey GudinMiami$356K
- Joseph PergolizziNaples$333K
- Ramon Cuevas-TrisanRiviera Beach$220K
- Navdeep JassalLakeland$163K
- Rodolfo GariTampa$120K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.